ZimVie's CEO Vafa Jamali joins Let's Talk Medtech in an exclusive interview about how the company is poised to transform the dental and spine markets.  The company has now been completely spun out from Zimmer Biomet and is trading on the Nasdaq. With strong leadership and a strong product portfolio, ZimVie is poised to be one of the breakout companies of the year in medtech.

It's American Heart Month & Cleerly's Dr. James Min shows how the company is using artificial intelligence to change the way we diagnose cardiovascular disease. 

Varian is changing the way we look at and treat cancer. Dr. Deepak 'Dee' Khuntia joins us for an incredible conversation about Varian's strategy in the fight against cancer.

A look at what's in store for medtech deals this year. Will 2022 be known as the year of Medtech M&A? Looks like it. EY's John Babitt joins us for a riveting conversation about EY's Annual M&A Firepower Report.

Omicron has caused quite a disruption in both pharma and medtech. Derron Stark EY-Parthenon Partner, Principal, Strategy Transactions, speaks about these supply chain issues.

Dr. Lishan Aklog wears multiple hats. He's the CEO of both PavMed and Lucid Diagnostics. Being a CEO of two companies during the pandemic can be tough at times, but Dr. Aklog's biggest challenge is getting out the awareness of how some instances of GERD can lead to Esophageal Cancer.

Dr. Aklog stops by for an amazing conversation on how Lucid Diagnostics is making an impact in the detection of Esophageal Cancer.

Paul Grand, MTI's CEO and Glenn Synder, Deloitte's Principle medtech practice leader discuss startups.